Patient with Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis, Acute Renal Failure, and Coronavirus Disease-19 Pneumonia: A Diagnostic and Therapeutic Challenge
DOI:
https://doi.org/10.3889/oamjms.2020.5510Keywords:
Antineutrophil cytoplasmic antibody-associated vasculitis, Coronavirus disease-19, Case reportAbstract
BACKGROUND: Antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) has a predilection for the kidney and more than three quarters of patients have renal involvement with rapidly progressive glomerulonephritis. Small-vessel systemic vasculitis may present as pulmonary-renal syndrome and is characterized by necrotizing glomerulonephritis and pulmonary hemorrhage. Diagnosis and therapy for AAV in coronavirus disease (COVID) COVID-19 pandemic require multi-disciplinary collaboration due to the affection of multiple systems and risks associated with immunosuppressive medications.
CASE REPORT: A 69-year-old non-smoker, non-diabetic female presented in the outpatient unit at the department of pulmonology with dry cough, malaise, and sub-febrile temperature, lasting for 1 month. The patient had a high suspicion of severe pulmonary-renal syndrome, ANCA-AAV, and acute renal failure requiring hemodialysis. She was treated with corticosteroids, cyclophosphamide, and plasma exchange. The treatment led to temporary improvement. Infections with COVID-19, Enterococcus in the urine, and Acinetobacter in the tracheal aspirate further complicated the clinical picture and despite antibiotic treatment, use of tocilizumab and convalescent plasma, the outcome was lethal.
CONCLUSION: It is important to establish the diagnosis and distinguish accurately between vasculitis and infection to provide adequate and timely therapy.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores- Suárez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30 Suppl 1:i14-22. https://doi.org/10.1093/ndt/gfv022 PMid:25805746 DOI: https://doi.org/10.1093/ndt/gfv022
Geetha D, Jefferson JA. ANCA-associated vasculitis: Core curriculum 2020. Am J Kidney Dis. 2020;75(1):124-37. https://doi.org/10.1053/j.ajkd.2019.04.031 PMid:31358311 DOI: https://doi.org/10.1053/j.ajkd.2019.04.031
Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCA-associated vasculitis: From pathogenesis to diagnosis. Clin Kidney J. 2015;8(3):343-350. https://doi.org/10.1093/ckj/sfv020 PMid:26034600 DOI: https://doi.org/10.1093/ckj/sfv020
McCabe C, Jones Q, Nikolopoulou A, Wathen C, Luqmani R. Pulmonary-renal syndromes: An update for respiratory physicians. Respir Med. 2011;105(10):1413-21. https://doi.org/10.1016/j.rmed.2011.05.012 PMid:21684732 DOI: https://doi.org/10.1016/j.rmed.2011.05.012
Uppal NN, Kello N, Shah HH, Khanin Y, de Oleo IR, Epstein E, et al. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney Int Rep. 2020;5(11):2079-83. https://doi.org/10.1016/j.ekir.2020.08.012 PMid:32839744 DOI: https://doi.org/10.1016/j.ekir.2020.08.012
Giollo A, Bixio R, Gatti D, Viapiana O, Idolazzi L, Dejaco C, et al. Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: A missed ‘window of opportunity. Ann Rheum Dis. 2020;???:??AQ6?. https://doi.org/10.1136/annrheumdis-2020-218830 PMid:32816699 DOI: https://doi.org/10.1136/annrheumdis-2020-218830
Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clin Imaging. 2020;66:35-41. https://doi.org/10.1016/j.clinimag.2020.05.013 PMid:32425338 DOI: https://doi.org/10.1016/j.clinimag.2020.05.013
Lee DW, Gardner R, Porter DL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188-95. https://doi.org/10.1182/blood-2015-07-656918 PMid:31265503 DOI: https://doi.org/10.1182/blood-2014-05-552729
Villiger PM, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmun Rev. 2010;9(12):812-9. PMid:20656070 DOI: https://doi.org/10.1016/j.autrev.2010.07.009
Berti A, Gall EC, Cornec D, Moura MC, Matteson EL, Crowson CS, et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant. 2019;34(9):1508-17. https://doi.org/10.1093/ndt/gfy250 PMid:30102330 DOI: https://doi.org/10.1093/ndt/gfy250
Masuda S, Nonokawa M, Futamata E, Nishibata Y, Iwasaki S, Tsuji T, et al. Formation and disordered degradation of neutrophil extracellular traps in necrotizing lesions of anti-neutrophil cytoplasmic antibody-associated vasculitis. Am J Pathol. 2019;189(4):839-46. https://doi.org/10.1016/j.ajpath.2019.01.007 PMid:30677396 DOI: https://doi.org/10.1016/j.ajpath.2019.01.007
Csernok E. Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev. 2003;2(3):158-64. https://doi.org/10.1016/s1568-9972(03)00010-7 PMid:12848957 DOI: https://doi.org/10.1016/S1568-9972(03)00010-7
Dąbrowska D, Jabłońska E, Garley M, Sawicka-Powierza J, Nowak K. The phenomenon of neutrophil extracellular traps in vascular diseases. Arch Immunol Ther Exp (Warsz). 2018;66(4):273-81. https://doi.org/10.1007/s00005-018-0505-y PMid:29404659 DOI: https://doi.org/10.1007/s00005-018-0505-y
Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. https://doi.org/10.1101/2020.04.30.20086736 PMid:32329756 DOI: https://doi.org/10.1172/jci.insight.138999
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583- 94. https://doi.org/10.1136/annrheumdis-2016-209133 PMid:27338776 DOI: https://doi.org/10.1136/annrheumdis-2016-209133
The Renal Association, Guidance for Clinicians with Patients Receiving Immunosuppression Treatment for Autoimmune Conditions of their Native Kidneys during COVID-19 Version 2; 2020.
Bomback AS, Canetta PA, Ahn W, Ahmad SB, Radhakrishnan J, Appel GB. How COVID-19 has changed the management of glomerular diseases. Clin J Am Soc Nephrol. 2020;15:876-9. https://doi.org/10.2215/cjn.04530420 PMid:32332048 DOI: https://doi.org/10.2215/CJN.04530420
Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, Mozo- Avellaneda L, Suárez-Cuervo C, Caminal-Montero L, et al. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis. 202AQ6 0;???:???. https://doi.org/10.1136/annrheumdis-2020-218246 PMid:32769153 DOI: https://doi.org/10.1136/annrheumdis-2020-218246
Gapud EJ, Kronbichler A, Gauckler P, Geetha D. Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. Eur J Rheumatol. 2020;7 Suppl 2:S121-8. https://doi.org/10.5152/eurjrheum.2020.2067 PMid:32716836 DOI: https://doi.org/10.5152/eurjrheum.2020.2067
Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397-402. https://doi.org/10.1038/ki.2013.131 PMid:23615499 DOI: https://doi.org/10.1038/ki.2013.131
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The eighth special issue. J Clin Apher. 2019;34(3):171-354. https://doi.org/10.1002/jca.21705 PMid:31180581 DOI: https://doi.org/10.1002/jca.21705
Tzouvelekis A, Karampitsakos T, Krompa A, Markozannes E, Bouros D. False positive COVID-19 antibody test in a case of granulomatosis with polyangiitis. Front Med (Lausanne). 2020;7:399. https://doi.org/10.3389/fmed.2020.00399 PMid:32733908 DOI: https://doi.org/10.3389/fmed.2020.00399
Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250-6. https://doi.org/10.1002/1529-0131(199707)40:7<1250::aid-art9>3.0.co;2-a PMid:9214425 DOI: https://doi.org/10.1002/art.1780400709
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467-74. PMid:32425643 DOI: https://doi.org/10.1016/j.ijid.2020.05.055
Ma TT, Huang YM, Wang C. Coagulation and fibrinolysis index profile in patients with ANCA-associated vasculitis. PLoS One. 2014;9(5):e97843. https://doi.org/10.1371/journal.pone.0097843 PMid:24842719 DOI: https://doi.org/10.1371/journal.pone.0097843
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care. 2020;8:49. https://doi.org/10.1186/s40560-020-00466-z PMid:32665858 DOI: https://doi.org/10.1186/s40560-020-00466-z
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954 PMid:32234467 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105954
Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: A cautionary case report. Chest. 2020;158(1):e15-9. https://doi.org/10.1016/j.chest.2020.04.024 PMid:32343968 DOI: https://doi.org/10.1016/j.chest.2020.04.024
Hani C, Trieu NH, Saab I, Dangeard S, Bennani S, Chassagnon G, et al. COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020;101(5):263-8. https://doi.org/10.1016/j.diii.2020.03.014 PMid:32291197 DOI: https://doi.org/10.1016/j.diii.2020.03.014
Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-18. PMid:32416116 DOI: https://doi.org/10.1016/j.kint.2020.05.006
Peleg Y, Kudose S, D’Agati V, Siddall E, Ahmad S, Kisselev S, et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int Rep. 2020;5(6):940-5. https://doi.org/10.1016/j.ekir.2020.04.017 PMid:32346659 DOI: https://doi.org/10.1016/j.ekir.2020.04.017
Rossi GM, Delsante M, Pilato FP, Gnetti L, Gabrielli L, Rossini G, et al. Kidney biopsy findings in a critically Ill COVID-19 patient with dialysis-dependent acute kidney injury: A case against SARS-CoV-2 nephropathy. Kidney Int Rep. 2020;5(7):1100-5. https://doi.org/10.1016/j.ekir.2020.05.005 PMid:32426558 DOI: https://doi.org/10.1016/j.ekir.2020.05.005
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Biljana Gerasimovska-Kitanovska, Gjulshen Selim, Zvezdana Petronijevik, Blagica Pecanova, Gjorgi Stojchev, Natasha Eftimovska-Otovic, Marija Zdravevska, Elena Jovanovska-Janeva, Dubravka Antova, Elena Curakova (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0